Affordable Medicines Facility-malaria

Last updated

The Affordable Medicines Facility-malaria (AMFm)
FoundedApril 2009 (2009-04) (launched) and July 2010 (2010-07) (began operations)
FocusInnovative financing mechanism to expand access to the most effective treatment for malaria, artemisinin-based combination therapies (ACTs)
Location
  • Geneva, Switzerland
Area served
Phase 1: Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania (mainland and Zanzibar), Uganda
Website www.theglobalfund.org/en/privatesectorcopayment/

The Affordable Medicines Facility-malaria (AMFm) is a financing mechanism intended to expand access to affordable and effective antimalarial medication (artemisinin-based combination therapies, ACTs). It works primarily through the commercial private sector, in addition to the public and non-governmental organization sectors which are the more traditional routes for development assistance in malaria control. Its goal is to drive down the price of the most effective malaria medicines so that millions of people can afford to buy them. [1] The program has been called "one of the most important recent advances in fighting malaria" and "a triumph of international cooperation." [1] The AMFm is hosted and managed by the Global Fund to Fight AIDS, Tuberculosis and Malaria in Geneva, Switzerland. [2]

Contents

The premise of the AMFm is that a factory-gate global subsidy, with measures to support its implementation, will save lives and reduce malaria-related mortality by increasing access to ACTs, and delay the onset of widespread resistance to the artemisinin in ACTs. It includes three elements: (i) price reductions through negotiations with ACT manufacturers, (ii) a buyer subsidy through a 'co-payment' at the top of the global supply chain and (iii) supporting interventions at the country level to promote the appropriate use of ACTs. [3]

AMFm Phase 1 was formally launched in April 2009 [4] and began operations in July 2010. [5] AMFm Phase 1 is being implemented through nine pilot programs in eight countries: Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania (mainland and Zanzibar) and Uganda. [5] There are early signs AMFm Phase 1 is effectively increasing availability and decreasing prices of ACTs; [6] however the Global Fund Board will only take a decision on the future of AMFm at the end of 2012 on the basis of an independent evaluation. [5] As part of the Copenhagen Consensus 2012, a panel of leading economists concluded that the AMFm was "one of the best returns on health that could be made globally" and ranked it two of 16 priority solutions to advance global welfare. [7]

In November 2012 the Global Fund Board decided to modify the existing AMFm business line by integrating lessons learned from Phase 1 into Global Fund core grant management and financial processes. The AMFm was subsequently renamed the Private Sector Co-payment Mechanism.

Background

Malaria is a life-threatening disease caused by parasites that are transmitted to humans through the bites of infected mosquitoes. Plasmodium falciparum is the species of the malaria parasite that causes the vast majority of severe disease and death. In 2010, there were about 216 million cases of malaria globally, and about 655,000 deaths – mostly among children in Africa. [8] Yet, malaria is preventable and treatable.

The most effective treatment for malaria are ACTs which combine artemisinin with another antimalarial medication. [9] ACTs are recommended by the World Health Organization (WHO) as first-line treatment for uncomplicated P. falciparum malaria [10] and, in 2004, the Global Fund to Fight AIDS, Tuberculosis and Malaria, the largest global funding source for malaria control, [11] began reprogramming all approved grants to procure ACTs in areas with high levels of drug resistance. [12] However, ACTs account for only one in five antimalarial treatments taken and, until the advent of the Affordable Medicines Facility-malaria (AMFm), were provided almost entirely by the public sector. [13] Over 60 percent of patients in malaria endemic areas access anti-malarial treatment through the private sector but, before the AMFm, the private sector only accounted for about 5 percent of all ACTs provided. [14] ACTs are more expensive than the less-effective first-line malaria treatments, such as chloroquine (CQ), sulfadoxine/pyrimethamine (SP) and amodiaquine (AQ), which usually cost less than US$1. [15] Therefore, unsubsidized, quality-assured ACTs are not affordable by many of the people who need them in malaria-endemic countries. [16] This leads to avoidable complications or death, since people either do not receive treatment or use cheaper, less effective antimalarials. Further, if patients use artemisinin monotherapies, this increases the risk of widespread resistance to artemisinin. [17]

The challenges noted above have been compounded by a mismatch between country realities and the channels through which ACTs financed by development aid were routed. [3] Whereas the commercial private sector plays a significant, sometimes dominant, role in many countries, donor-funded ACTs have been traditionally channeled mostly through the public sector and not-for-profit private sector. These factors, combined with an insufficiency of ACTs relative to the burden of malaria, resulted in poor access to ACTs at country level and persistent use of inappropriate alternatives. [3]

Origins

In 2004, the United States Institute of Medicine called for a global co-payment toward purchases of ACTs by first-line buyers directly from drug manufacturers. [18] This call stemmed from the recommendations of the IOM committee chaired by Nobel Laureate economist Professor Kenneth Arrow, which were published in Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance. [19] The IOM committee advocated for "a sustained global subsidy of artemisinin co-formulated with other antimalarial drugs in order to reduce malaria mortality ("saving lives") and delay resistance ("buying time")" until new categories of antimalarials could be developed. [19] The proposed buyer co-payment for quality-assured ACTs would be available to both the public and private sectors. Arrow explained, "When I discovered that 70% of chloroquine was distributed commercially, I immediately came to the conclusion that ACTs would have to be distributed through the private sector if we wanted nearly universal coverage." [16] Subsequent analyses published in peer-reviewed journals reconfirmed the potential impact of the IOM committee proposal. [20]

Better access to ACTs is an essential part of the comprehensive package of interventions required to fight malaria that includes prevention (insecticide-treated nets, indoor residual spraying, other vector control techniques and in development of malaria vaccines) and treatments for severe malaria. [21]

Establishment

The Roll Back Malaria (RBM) Partnership, in collaboration with the World Bank and the Bill & Melinda Gates Foundation, initiated work in 2006 to implement the IOM proposal; the key technical design principles of the AMFm were developed and endorsed in 2007. [14] The Global Fund to Fight AIDS, Tuberculosis and Malaria was invited to host the AMFm and, in 2008, the Global Fund Board approved the implementation plan and policy framework for a limited Phase 1 of the AMFm: the launch of the AMFm would be phased, beginning with a limited number of countries (approximately 290 million ACT treatments to be supplied over two years); Phase 1 of the AMFm will be assessed via an independent technical evaluation; the findings of this evaluation would be reviewed by the Global Fund Board in 2010 to decide whether to proceed to global roll out of the AMFm. [22] [23] Following this approval, preparations began for the launch of the AMFm in 2009. [4]

Elements

AMFm Phase 1 has three elements: (i) price reductions through negotiations with ACT manufacturers, (ii) a buyer subsidy through a 'co-payment' at the manufacturer level of the global supply chain and (iii) supporting interventions to promote appropriate use of ACTs. [14]

Implementation

AMFm Phase 1 was formally launched in April 2009 [4] and began operations in July 2010. [5] Eleven countries were invited to participate in the pilot and eight countries (nine pilots) were ultimately approved by January 2010: Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania (mainland and Zanzibar) and Uganda. [5] Given the delays associated with the startup of AMFm Phase 1, the Global Fund Board extended the implementation period of AMFm Phase 1 by six months to end 2012. [24]

Related Research Articles

<span class="mw-page-title-main">Malaria</span> Mosquito-borne infectious disease

Malaria is a mosquito-borne infectious disease that affects humans and other vertebrates. Human malaria causes symptoms that typically include fever, fatigue, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin 10 to 15 days after being bitten by an infected Anopheles mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.

Antimalarial medications or simply antimalarials are a type of antiparasitic chemical agent, often naturally derived, that can be used to treat or to prevent malaria, in the latter case, most often aiming at two susceptible target groups, young children and pregnant women. As of 2018, modern treatments, including for severe malaria, continued to depend on therapies deriving historically from quinine and artesunate, both parenteral (injectable) drugs, expanding from there into the many classes of available modern drugs. Incidence and distribution of the disease is expected to remain high, globally, for many years to come; moreover, known antimalarial drugs have repeatedly been observed to elicit resistance in the malaria parasite—including for combination therapies featuring artemisinin, a drug of last resort, where resistance has now been observed in Southeast Asia. As such, the needs for new antimalarial agents and new strategies of treatment remain important priorities in tropical medicine. As well, despite very positive outcomes from many modern treatments, serious side effects can impact some individuals taking standard doses.

<i>Artemisia annua</i> Herb known as sweet wormwood used to treat malaria

Artemisia annua, also known as sweet wormwood, sweet annie, sweet sagewort, annual mugwort or annual wormwood, is a common type of wormwood native to temperate Asia, but naturalized in many countries including scattered parts of North America.

<span class="mw-page-title-main">Artemisinin</span> Group of drugs used against malaria

Artemisinin and its semisynthetic derivatives are a group of drugs used in the treatment of malaria due to Plasmodium falciparum. It was discovered in 1972 by Tu Youyou, who shared the 2015 Nobel Prize in Physiology or Medicine for her discovery. Artemisinin-based combination therapies (ACTs) are now standard treatment worldwide for P. falciparum malaria as well as malaria due to other species of Plasmodium. Artemisinin is extracted from the plant Artemisia annua a herb employed in Chinese traditional medicine. A precursor compound can be produced using a genetically engineered yeast, which is much more efficient than using the plant.

<span class="mw-page-title-main">Artesunate</span> Chemical compound

Artesunate (AS) is a medication used to treat malaria. The intravenous form is preferred to quinine for severe malaria. Often it is used as part of combination therapy, such as artesunate plus mefloquine. It is not used for the prevention of malaria. Artesunate can be given by injection into a vein, injection into a muscle, by mouth, and by rectum.

<span class="mw-page-title-main">The Global Fund to Fight AIDS, Tuberculosis and Malaria</span> International organization

The Global Fund to Fight AIDS, Tuberculosis and Malaria is an international financing and partnership organization that aims to "attract, leverage and invest additional resources to end the epidemics of HIV/AIDS, tuberculosis and malaria to support attainment of the Sustainable Development Goals established by the United Nations". This multistakeholder international organization maintains its secretariat in Geneva, Switzerland. The organization began operations in January 2002. Microsoft founder Bill Gates was one of the first donors to provide seed money for the partnership. From January 2006 it has benefited from certain US Privileges, Exemptions, and Immunities under executive order 13395, which conferred International Organizations Immunities Act status on it.

Artemether/lumefantrine, sold under the trade name Coartem among others, is a combination of the two medications artemether and lumefantrine. It is used to treat malaria caused by Plasmodium falciparum that is not treatable with chloroquine. It is not typically used to prevent malaria. It is taken by mouth.

<span class="mw-page-title-main">Drugs for Neglected Diseases Initiative</span> Non-profit organization

The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.

<span class="mw-page-title-main">Dihydroartemisinin</span> Drug used to treat malaria

Dihydroartemisinin is a drug used to treat malaria. Dihydroartemisinin is the active metabolite of all artemisinin compounds and is also available as a drug in itself. It is a semi-synthetic derivative of artemisinin and is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs. It is sold commercially in combination with piperaquine and has been shown to be equivalent to artemether/lumefantrine.

<span class="mw-page-title-main">Unitaid</span> Global health initiative

Unitaid is a global health initiative that works with partners to bring about innovations to prevent, diagnose and treat major diseases in low- and middle-income countries, with an emphasis on tuberculosis, malaria, and HIV/AIDS and its deadly co-infections. Founded in 2006, the organization funds the final stages of research and development of new drugs, diagnostics and disease-prevention tools, helps produce data supporting guidelines for their use, and works to allow more affordable generic medicines to enter the marketplace in low- and middle-income countries. Hosted by the World Health Organization (WHO) in Geneva, Unitaid was established by the governments of Brazil, Chile, France, Norway and the United Kingdom.

<span class="mw-page-title-main">Health in Cambodia</span>

The quality of health in Cambodia is rising along with its growing economy. The public health care system has a high priority from the Cambodian government and with international help and assistance, Cambodia has seen some major and continuous improvements in the health profile of its population since the 1980s, with a steadily rising life expectancy.

<span class="mw-page-title-main">Piperaquine</span> Chemical compound

Piperaquine is an antiparasitic drug used in combination with dihydroartemisinin to treat malaria. Piperaquine was developed under the Chinese National Malaria Elimination Programme in the 1960s and was adopted throughout China as a replacement for the structurally similar antimalarial drug chloroquine. Due to widespread parasite resistance to piperaquine, the drug fell out of use as a monotherapy, and is instead used as a partner drug for artemisinin combination therapy. Piperaquine kills parasites by disrupting the detoxification of host heme.

Project 523 is a code name for a 1967 secret military project of the People's Republic of China to find antimalarial medications. Named after the date the project launched, 23 May, it addressed malaria, an important threat in the Vietnam War. At the behest of Ho Chi Minh, Prime Minister of North Vietnam, Zhou Enlai, the Premier of the People's Republic of China, convinced Mao Zedong, Chairman of the Chinese Communist Party, to start the mass project "to keep [the] allies' troops combat-ready", as the meeting minutes put it. More than 500 Chinese scientists were recruited. The project was divided into three streams. The one for investigating traditional Chinese medicine discovered and led to the development of a class of new antimalarial drugs called artemisinins. Launched during and lasting throughout the Cultural Revolution, Project 523 was officially terminated in 1981.

The Medicines Patent Pool (MPP) is a Unitaid-backed international organisation founded in July 2010, based in Geneva, Switzerland. Its public health driven business model aims to lower the prices of HIV, tuberculosis and hepatitis C medicines and facilitate the development of better-adapted HIV treatments through voluntary licensing and patent pooling. Its goal is to improve access to affordable and appropriate HIV, hepatitis C and tuberculosis medicines in low- and middle-income countries (LMIC). In May 2020, the MPP become an implementing partner of the WHO's Covid-19 Technology Access Pool (C-TAP).

Piperaquine/dihydroartemisinin (DHA/PPQ), sold under the brand name Eurartesim among others, is a fixed dose combination medication used in the treatment of malaria. It is a combination of piperaquine and dihydroartemisinin. Specifically it is used for malaria of the P. falciparum and P. vivax types. It is taken by mouth.

The Amazon Malaria Initiative (AMI) was a regional program that was created in 2001 by several countries sharing the Amazon basin with technical support from PAHO/WHO and financial support from the U.S. Agency for International Development (USAID), and managed by USAID/Peru as part of its South American Regional Infectious Disease Program (SARI). The initiative used a multi-pronged approach to achieve the overall aims of preventing and controlling malaria and reducing malaria-related morbidity and mortality in countries of the Americas. AMI priorities for malaria prevention are as follows, diagnosis and treatment, drug resistance and epidemiological surveillance, vector control, pharmaceutical management, quality of medicines, communication and networking.

Dalberg Global Development Advisors is a strategy and policy advisory firm. Founded in 2001, the company specializes in global development. Dalberg has worked in over 90 countries with over 400 clients including governments, foundations, international agencies, non-governmental organizations, and Fortune 500 companies. Its mission is to raise living standards in developing countries and mobilize effective responses to the world's most pressing issues.

Adrianus Mattheus Dondorp is a Dutch intensivist, infectious diseases physician, and head of the Mahidol Oxford Tropical Medicine Research Unit in Bangkok. He is best known for his research in severe falciparum malaria, a disease that requires intensive care in hospital. He chairs the World Health Organization Technical Expert Group on antimalarial medication drug resistance and containment.

<span class="mw-page-title-main">Ramanan Laxminarayan</span> Economist and epidemiologist

Ramanan Laxminarayan Ph.D., M.P.H., FIDSA is an economist and an epidemiologist. He is founder and director of the One Health Trust – formerly known as the Center for Disease Dynamics, Economics & Policy (CDDEP) – in Washington, D.C., and director of the World Health Organization Collaborating Center for Antimicrobial Resistance. Laxminarayan is a senior research scholar at Princeton University, an affiliate professor at the University of Washington, a senior associate at the Johns Hopkins Bloomberg School of Public Health, and a visiting professor at the University of Strathclyde. In 2023, he was appointed an honorary visiting professor at the National University of Singapore Saw Swee Hock School of Public Health. His research on epidemiological models of infectious diseases and economic analysis of drug resistance, and research on public health gets attention from leaders and policymakers worldwide. He served on the President Obama's Council of Advisors on Science and Technology’s antimicrobial resistance working group. He served as a voting member of the U.S. Presidential Advisory Council on Combating Antimicrobial Resistance from 2015 to 2023. He has served as chairperson of the Global Antibiotic Research and Development Partnership (GARDP), a not-for-profit organization dedicated to developing new antimicrobials, since its founding. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases Initiative (DNDi).

Sanjeev Krishna,, is a British physician and parasitologist whose research focuses on affordable diagnosis and treatment of diseases such as COVID-19, malaria, Ebola, African trypanosomiasis, leishmaniasis, and colorectal cancer. Krishna is Professor of Medicine and Molecular Parasitology at St George's, University of London and St George's Hospital.

References

  1. 1 2 McNeil, Donald G. Jr. (17 April 2009). "Plan Tries to Lower Malaria Drug Cost". The New York Times. Retrieved 24 May 2012.
  2. ↑ "Affordable Medicines Facility-malaria (AMFm)". The Global Fund to Fight AIDS, Tuberculosis and Malaria. Archived from the original on 18 April 2009. Retrieved 30 April 2012.
  3. 1 2 3 Adeyi, Olusoji; Rifat Atun (27 November 2010). "Universal access to malaria medicines: innovation in financing and delivery". The Lancet. 376 (9755): 1869–1871. doi:10.1016/S0140-6736(10)61189-0. PMID   20940074. S2CID   9497597 . Retrieved 30 September 2011.
  4. 1 2 3 "$225 million partnership to bring effective malaria drugs to all who need them". The Global Fund to Fight AIDS, Tuberculosis and Malaria Press Release. 17 April 2009. Archived from the original on 23 October 2011. Retrieved 30 September 2011.
  5. 1 2 3 4 5 "Affordable Medicines Facility-malaria Frequently Asked Questions". Archived from the original on 6 July 2011. Retrieved 30 September 2011.
  6. ↑ Press Release. "Global Fund-led initiative slashes cost of anti-malaria medicines in many African countries". Global Fund. Archived from the original on 5 May 2012. Retrieved 2 May 2012.
  7. ↑ "Copenhagen Consensus 2012 - Outcomes". Copenhagen Consensus. Retrieved 14 May 2012.
  8. ↑ "World Malaria Report 2011". World Health Organization. Archived from the original on 10 January 2012. Retrieved 30 April 2012.
  9. ↑ "Facts on ACTs". World Health Organization. Archived from the original on 17 October 2011. Retrieved 30 September 2011.
  10. ↑ "WHO releases new malaria guidelines for treatment and procurement of medicines". Archived from the original on 10 March 2010. Retrieved 30 September 2011.
  11. ↑ "The Global Fund to Fight AIDS, TB, and Malaria". Archived from the original on 7 September 2011. Retrieved 30 September 2011.
  12. ↑ Shretta, Rima. "Global Fund Grants for Malaria: Lessons Learned in the Implementation of ACT Policies in Nigeria" (PDF). Archived from the original (PDF) on 12 July 2011. Retrieved 30 September 2011.
  13. ↑ Coll-Seck, Awa Marie. "Advances in the Management of Malaria –" (PDF). Retrieved 30 September 2011.[ permanent dead link ]
  14. 1 2 3 "Affordable Medicines Facility-malaria Technical Design" (PDF). Archived from the original (PDF) on 12 July 2011. Retrieved 30 September 2011.
  15. ↑ "ACT Watch Results". Archived from the original on 8 September 2011. Retrieved 30 September 2011.
  16. 1 2 Maxmen, Amy (4 May 2012). "Malaria subsidy pilot soars, but some see turbulence ahead". Nature. Retrieved 24 May 2012.
  17. ↑ Yeung, Sheunmay; Wirichada Pongtavornpinyo; Ian M. Hastings; Anne J. Mills (2004). "Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to policy choices" (PDF). Am. J. Trop. Med. Hyg. 71 (Suppl 2) (2_suppl): 179–186. doi:10.4269/ajtmh.2004.71.179. S2CID   5642756 . Retrieved 30 September 2011.
  18. ↑ Stencel, Christine (20 July 2004). "Up to $500 Million Needed Annually for Subsidy to Make Artemisinin Combination Therapy the First-Line Treatment for Malaria Worldwide". News from the National Academies. Retrieved 30 September 2011.
  19. 1 2 Arrow, Kenneth (2004). Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance. Washington, DC: National Academies Press. ISBN   978-0-309-09218-0.
  20. ↑ Laxminarayan, Ramanan; Mead Over; David L. Smith (2006). "Will A Global Subsidy of New Antimalarials Delay The Emergence of Resistance And Save Lives?". Health Affairs. 25 (2): 325–336. doi: 10.1377/hlthaff.25.2.325 . PMID   16522574.
  21. ↑ "Global Malaria Action Plan". Roll Back Malaria Partnership. Archived from the original on 10 July 2011. Retrieved 30 September 2011.
  22. ↑ "Eighteenth Board Meeting Decision Points". The Global Fund to Fight AIDS, Tuberculosis, and Malaria. Archived from the original on 3 February 2016. Retrieved 30 September 2011.
  23. ↑ "Report of the AMFm Ad Hoc Committee (18th Meeting of the Global Fund Board)". The Global Fund to Fight AIDS, Tuberculosis and Malaria. Archived from the original on 3 February 2016. Retrieved 30 September 2011.
  24. ↑ "Decision Points of 22nd Meeting of the Global Fund Board". The Global Fund to Fight AIDS, Tuberculosis, and Malaria. Archived from the original on 6 August 2011. Retrieved 30 September 2011.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.